Generic placeholder image

Letters in Drug Design & Discovery

Author(s): Ítalo Antônio Fernandes, Tamiris Maria de Assis, Isael Aparecido Rosa and Elaine Fontes Ferreira da Cunha*

DOI: 10.2174/1570180815666180528090945

DownloadDownload PDF Flyer Cite As
Indolin-2-one Derivatives: Theoretical Studies Aimed at Finding More Potent Aurora B Kinase Inhibitors

Page: [138 - 152] Pages: 15

  • * (Excluding Mailing and Handling)

Abstract

Background: Aurora kinases perform important roles in mammals, mainly in cell cycle. Overexpression of these enzymes is related to tumor development and is indicative of worsening of clinical conditions. Aurora kinases are promising targets in the search for new anticancer drugs, in particular, Aurora B.

Methods: This work was designed to study and understand the interactions between human Aurora B and several indolin-2-one derivatives, structurally similar to sunitinib. MVD software was utilized in docking analyses of indolin-2-one derivatives. Human Aurora B kinase was obtained from the PDB (4AF3) and redocked with hesperadin, which was used as a reference compound. The predicted model of the training group, considering 21 amino acid residues, performed in Chemoface, achieved an R2 of 0.945, suggesting that the binding conformations of the ligands with human Aurora B are reasonable and the data can be used to predict the interaction energy of other Aurora B inhibitors indolin-2-one derivatives.

Results: MolDock Score energy for compound 1 showed more stable interaction energy (-225.90 kcal.mol-1) then the other inhibitors studied, while sunitinib was the least stable (-135.63 kcal.mol-1). Compounds 1-45, hesperadin and sunitinib, interacted with Glu171 (–NH from indolinonic moiety), and the majority of them with Ala173 (C=O from indolinonic moiety) via hydrogen bonds, thus these two residues are relevant for potency.

Conclusion: Docking studies and biological activity in literature show subunits likely for structural optimizations, leading to four new proposed derivatives (IAF61, IAF63, IAF66, IAF79) as promising compounds for synthesis and biological evaluation against human Aurora B, validating and ratifying the docking studies.

Keywords: Aurora B kinase, aurora B kinase inhibitors, indolin-2-one derivatives, cancer, medicinal chemistry, anticancer compounds, computational chemistry, docking.

Graphical Abstract

[1]
Carmena, M.; Earnshaw, W.C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol., 2003, 4(11), 842-854.
[2]
Lee, E.C.; Frolov, A.; Li, R.; Ayala, G.; Greenberg, N.M. Targeting aurora kinases for the treatment of prostate cancer. Cancer Res., 2006, 66(10), 4996-5002.
[3]
Zeng, W.F.; Navaratne, K.; Prayson, R.A.; Weil, R.J. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J. Clin. Pathol., 2007, 60(2), 218-221.
[4]
Cheung, C.H.; Coumar, M.S.; Hsieh, H.P.; Chang, J.Y. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin. Investig. Drugs, 2009, 18(4), 379-398.
[5]
Elkins, J.M.; Santaguida, S.; Musacchio, A.; Knapp, S. Crystal structure of human aurora B in complex with INCENP and VX-680. J. Med. Chem., 2012, 55(17), 7841-7848.
[6]
Yang, J.; Ikezoe, T.; Nishioka, C.; Tasaka, T.; Taniguchi, A.; Kuwayama, Y.; Komatsu, N.; Bandobashi, K.; Togitani, K.; Koeffler, H.P.; Taguchi, H.; Yokoyama, A. AZD1152, a novel and selective Aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood, 2007, 110, 2034-2040.
[7]
Ju, S.; Xu, P.; Yang, X.; Sozar, S.; Muneri, C.W.; Xu, Y.; Chen, C.; Cui, P.; Xu, W.; Rui, R. Aurora B inhibitor barasertib prevents meiotic maturation and subsequent embryo development in pig oocytes. Theriogenology, 2016, 86(2), 503-515.
[8]
Tyler, R.K.; Shpiro, N.; Marquez, R.; Eyers, P.A. VX-680 inhibits aurora A and aurora B kinase activity in human cells. Cell Cyc, 2007, 6(22), 2846-2854.
[9]
Ditchfield, C.; Johnson, V.L.; Tighe, A.; Ellston, R.; Haworth, C.; Johnson, T.; Mortlock, A.; Keen, N.; Taylor, S.S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol., 2003, 161(2), 267-280.
[10]
Hauf, S.; Cole, R.W.; Laterra, S.; Zimmer, C.; Schnapp, G.; Walter, R.; Heckel, A.; Van Meel, J.; Rieder, C.L.; Peters, J.M. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol., 2003, 161(2), 281-294.
[11]
Determann, R.; Dreher, J.; Baumann, K.; Preu, L.; Jones, P.G.; Totzke, F.; Schächtele, C.; Kubbutat, M.H.G.; Kunick, C. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines - A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines. Eur. J. Med. Chem., 2012, 53, 254-263.
[12]
Chern; J.W.; Jagtap, A.D.; Wang, H.C.; Chen, G.S. Indolin-2-one derivatives as protein kinase inhibitors. U.S. Patent 2013/158373, October 24, 2013.
[13]
Gehlhaar, D.K.; Verkhivker, G.M.; Rejto, P.A.; Sherman, C.J.; Fogel, D.R.; Fogel, L.J.; Freer, S.T. molecular recognition of the inhibitor Ag-1343 by hiv-1 protease: Conformationally flexible docking by evolutionary programming. Chem. Biol., 1995, 2(5), 317-324.
[14]
Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem., 2006, 49(11), 3315-3321.
[15]
Sessa, F.; Mapelli, M.; Ciferri, C.; Tarricone, C.; Areces, L.B.; Schneider, T.R.; Stukenberg, P.T.; Musacchio, A. Mechanism of Aurora B Activation by INCENP and Inhibition by Hesperadin. Mol. Cell, 2005, 18(3), 379-391.
[16]
Hopfinger, A.J.; Wang, S.; Tokarski, J.S.; Jin, B.; Albuquerque, M.; Madhav, P.J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc., 1997, 119(43), 10509-10524.